Takeda (TAK) recently disclosed that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended that fruquintinib be approved. Fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors, has been suggested for the treatment of adult patients previously treated for metastatic colorectal cancer or mCRC. Takeda has stated that, upon approval, fruquintinib will stand as the first and only inhibitor applicable to all three VEGF receptors within the European Union for previously treated mCRC patients.
The United States Food and Drug Administration had formerly approved fruquintinib in November 2023. Marketed as FRUZAQLA, the product has found general acceptance within health circles.
For more cutting-edge health news, navigate your browser to rttnews.com.
